To fully characterise tumor growth-promoting effects of X10 in comparison to HI in vivo it is necessary to further explore the effect of doses and pharmacokinetics on growth of allografts, and also to test other cell lines derived from obesity- and diabetes-relevant cancers and/or with a different ratio between IGF-1Rs and IRs in allograft experiments. The gene discussed is IARS1; the disease is cancer.